Qiagen stock slips after earnings beat narrows upside

Published on 09/20/2026 at 15:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Qiagen stock closed at USD 43.37 on September 18, 2026 on the NYSE, about 8.4% below its level at the start of 2026. Recent results showed an earnings beat with estimated fair value roughly 5% above the current price.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

Qiagen N.V. (ISIN NL0012169213) stock closed at USD 43.37 on the New York Stock Exchange on September 18, 2026, down 2.27% from the prior session and around 8.4% below its level at the start of 2026.

Earnings beat but limited upside

According to Simply Wall St on September 19, 2026, Qiagen recently reported quarterly results that came in ahead of earnings expectations, prompting a discussion of how investors might respond to the earnings beat and the company’s valuation.

The same analysis notes that Qiagen’s estimated fair value stands about 5% above the current share price, suggesting only modest upside potential if the valuation gap closes.

Price, range and valuation

Per data from MarketBeat, Qiagen stock finished trading at USD 43.37 on September 18, 2026, with the prior close higher by 2.27%, implying the stock fell by that amount on the day.

MarketBeat also shows a 52-week trading range between USD 32.53 and USD 57.81 as of September 18, 2026, placing the latest closing price roughly midway between the low and the high and more than USD 10.00 below the top of the range.

At the USD 43.37 closing level, MarketBeat reports that Qiagen’s market capitalization is about USD 8.94 billion as of September 18, 2026, underscoring its position as a mid-cap player in the molecular diagnostics and life sciences tools market.

Analyst consensus and targets

According to MarketBeat on September 18, 2026, Qiagen carries a consensus rating of Hold based on coverage from 14 analysts, with the average rating score at 2.43 on a 0 to 4 scale.

The same MarketBeat overview cites a consensus price target of USD 43.51 for Qiagen, with individual targets ranging from USD 38.60 to USD 50.00, indicating that the average target is only USD 0.14, or roughly 0.3%, above the most recent closing price of USD 43.37.

For investors, this narrow gap between price and consensus target underlines that the market already prices in much of the expected earnings improvement, making future revisions to guidance or new growth catalysts pivotal for a stronger move in Qiagen stock.

Stock level and investor perspective

Qiagen stock closed at USD 43.37 on the NYSE on September 18, 2026, compared with about USD 47.34 at the beginning of 2026, leaving the shares down 8.4% year-to-date while still trading comfortably above the 52-week low but well below the high.